While it is common knowledge that oncology is an umbrella term used for the branch of science, dedicated wholly to study and treat cancer, not many people have open access to publications that can be helpful when a need arises. Also, the majority of online bio-journals rarely focus on being updated with new technologies and breakthroughs in the oncology department which leaves us with a great divide between a want for information versus readily available matter.
Oncotarget was established in 2010, as a peer-reviewed platform, allows people to get open access to detailed research material in the field of oncology. The sole purpose of this bio-medical journal is to focus primarily on areas specific to cancer, get information on any and all relevant targets while providing an overview of the complexity of this branch of medical science. Check Oncotarget at scimagojr.com
Oncotarget has opted for a power move that has made this bio-journal stand out from the rest. Papers are posted on this platform as frequently as twice a week usually on Tuesdays and Fridays. While some of the research material offers insight on translational along with clinical research, a lot of the other content shared on this platform allow invaluable access to paradigm-shifting and meticulously constructed reviews. Both perspectives and opinions are posted on this platform in a uniquely desirable way. Learn more about Oncotarget at Eurekalert.org.
The archives of Oncotarget are filled with information that has been collected over the years and one of the examples of relevant and factual content posted is the video interview with Dr. Carmelo Nucera. This video along with the detailed written paper focused on explaining various aspects of the reoccurrence of papillary thyroid carcinoma in patients who have been in remission for many months to years. The material posted also highlighted on some interesting facts such as thyroid cancer tends to become drug resistance over time, the new finding by the Harvard Medical School, a plausible treatment with the FDA approved drug palbociclib and how this versatile drug can help in preventing the onset of vemurafenib resistance. The detailed paper posted by Oncotarget also mentioned the results of using this medicine and this information got published on their cover on October 18, 2017.
Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget